Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,498 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06277947 | Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward(GARD-HIPEC) | unknown | N/A | 92 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05701735 | Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer(CECIL) | unknown | N/A | 45 | University of Santo Tomas Hospital, PhilippinesOTHER |
| 1 |
| Feb 23, 2024 |
| clinicaltrials |
| NCT05297552 | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06251492 | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06243185 | Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors | unknown | Phase 2 | 30 | Fengzhi FengOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06241105 | Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 69 | Peking Union Medical College HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05212779 | Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease | unknown | — | 45 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06236958 | Effect of Early Enteral Nutrition on Postoperative Recovery of Ovarian Cancer Patients | unknown | — | 200 | Luo ChengyanOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06235268 | Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma | unknown | — | 1,000 | Federation of Italian Cooperative Oncology GroupsOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05489926 | A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure | unknown | Phase 2 | 15 | Zhejiang Cancer HospitalOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06223763 | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery(SUROVA) | unknown | — | 5,000 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04994197 | Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS | unknown | — | 970 | Ruijin HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06182735 | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma | unknown | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06178601 | A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 36 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT02969083 | Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma(URANUS) | unknown | Phase 2 | 200 | The European Uro-Oncology GroupOTHER | 3 | Dec 18, 2023 | clinicaltrials |
| NCT03108703 | Assessment of QoL and Outcomes With SBRT for RCC(AQuOS-RCC) | unknown | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04040530 | Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours | unknown | — | 187 | Region of Southern DenmarkOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06134700 | Low Pressure Versus Standard Pressure Pneumoperitoneum in Laparoscopic Nephrectomy | unknown | N/A | 44 | Institute of medicine, Maharagjung medical campusOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06129955 | Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT06120413 | 18F-LN1 PET/CT in Urothelial Carcinomas | unknown | — | 30 | Sichuan Provincial People's HospitalOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06113367 | Immunotherapy in Upper Tract Urothelial Carcinoma(VESUVIO) | unknown | — | 350 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06085456 | Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study | unknown | — | 1,000 | RenJi HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05176145 | Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test(DMIA) | unknown | N/A | 400 | VitadxOTHER | 3 | Oct 13, 2023 | clinicaltrials |
| NCT06074484 | A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01949337 | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | unknown | Phase 3 | 1,311 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 28, 2023 | clinicaltrials |
| NCT05919524 | SBRT With Focal Dose Escalation on DIL in Localized Prostate Cancer(SAFO) | unknown | N/A | 27 | Almudena ZapateroOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06049030 | A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma | unknown | Phase 1 | 190 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05534854 | Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT06010667 | A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | — | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05420519 | Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | unknown | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05420545 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05468190 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | unknown | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05856409 | Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence | unknown | — | 20 | RenJi HospitalOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma(MARIO-3) | unknown | Phase 2 | 91 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05874115 | Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer(OutCoME) | unknown | — | 75 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05558956 | Total Body PET-CT Imaging of Prostate Cancer Using Illuccix | unknown | Early Phase 1 | 100 | BAMF HealthOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05879471 | 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 39 | Peking Union Medical College HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05955209 | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 21, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 26, 2024source: clinicaltrials